Menu

Search

  |   Business

Menu

  |   Business

Search

Methicillin-resistant Staphylococcus aureus (MRSA) Infection Therapeutics Pipeline Supported by Research Funding from Various Agencies: P&S Market Research

NEW YORK, March 21, 2018 -- According to a new research report titled Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics Pipeline Analysis 2018” published by P&S Market Research, MRSA therapeutics currently exhibits a proliferating pipeline with 52 drug candidates.

Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/mrsa-therapeutics-pipeline/report-sample

MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different stages of development.

According to the research findings, a majority of the drug candidates for the treatment of MRSA are being developed to be administered by the intravenous route which offers good bioavailability and is considered to be more effective at the target site.

The players in the MRSA therapeutics pipeline have been receiving increasing support from various organizations in the form of research funding. For instance, Microbiotix Inc received Phase l grants from SBIR for “Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus” for a term of two years in February 2012.

Browse Full Report with detailed TOC on “MRSA Infection Therapeutics Pipeline” at: https://www.psmarketresearch.com/market-analysis/mrsa-therapeutics-pipeline

It has been observed that most of the companies are developing drug candidates with novel mechanism of action. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, GlaxoSmithKline plc is developing a Phase II drug candidate, GSK 2140944 or Gepotidacin. It is an intravenous, synthetic, Type II topoisomerase inhibitor. If GSK2140944 hits the market, it would be the first topoisomerase inhibitor for gram-negative infections. Savara Pharma's AeroVanc is the first inhaled antibiotic being developed and is in the Phase III stage of clinical trial and has received $5 million fund from Nonprofit Cystic Fibrosis Foundation. If the drug receives the approval, it would be the first inhaled antibiotic to be developed for the treatment of MRSA.

Some of the key players involved in the development of MRSA therapeutics include GlaxoSmithKline plc, Crystal Genomics Inc., and Innovation Pharmaceuticals Inc.

More Reports Published by P&S Market Research

Myelofibrosis Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/myelofibrosis-therapeutics-pipeline-analysis

BET Inhibitors Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Primary Logo

  • Market Data
Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.